物质信息
ID:73193
名称和标识
IUPAC标准名
(1S,10R,11S,14S,15S)-4-methoxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-triene-5,14-diol
别名
2-Methoxyestradiol2-ME2
IUPAC传统名
2-methoxyestradiol
数据登录号
CAS号
化合物性质
产品相关信息
成盐信息
Free Base
安全信息
保存条件
-20°C
药理学性质
作用靶点
HIF
描述信息
Research Area
Description
Pulmonary hypertension
Biological Activity
Description
2-Methoxyestradiol is an endogenous estrogen metabolite and naturally occurring mammalian tubulin polymerization inhibitor.
Targets
IC50
In Vitro
2-Methoxyestradiol exhibits the inhibitory activity of cellular proliferation in a breast carcinoma cell line MDA-MB-435 and an ovarian carcinoma cell line SK-OV-3 with IC50 of 1.38 μM and 1.79 μM, respectively. Furthermore, 2-Methoxyestradiol also inhibits cellular microtubule depolymerization in rat aortic smooth muscle A-10 cells with EC50 of 7.5 μM. [1] 2-Methoxyestradiol inhibits proliferation of MCF-7 and BM cells with IC50 of 52 μM and 8 μM. [2] In MDA-MB-231 cells, 2-Methoxyestradiol inhibits HIF-1-mediated transcriptional activation of target genes without affecting the transcription of HIF-1α itself. [3] A recent study shows that 2-Methoxyestradiol (0.5 μM), blocks TGF-β3-induced expression of collagen (Col) type I(αI), Col III(αI), plasminogen activator inhibitor (PAI) 1, connective tissue growth factor (CTGF), and α-smooth muscle actin (α-SMA). Moreover, 2-Methoxyestradiol ameliorates TGF-β3-induced Smad2/3 phosphorylation and nuclear translocation, and inhibits TGF-β3-induced activation of the PI3K/Akt/mTOR pathway. [4]
In Vivo
In a 9L rat glioma (9L-V6R) rat model, 2-Methoxyestradiol significantly decreases HIF-1 activity and inhibits the tumor growth in a dose-dependent manner by 4-fold reduction for 60 mg/kg/day, and 23-fold reduction for 600 mg/kg/day, respectively. [5]
Clinical Trials
2-Methoxyestradiol is currently in Phase II clinical trials in patients with plateau Phase or relapsed multiple myeloma. Combination treatment of 2-Methoxyestradiol and Bevacizumab is currently in Phase II clinical trials in patients with locally advanced or metastatic carcinoid tumors.
Features
Combination Therapy
Description
While the combination of 2-Methoxyestradiol and 4-Hydroxytamoxifen leads to the more potent inhibition of proliferation of MCF-7 and BM cells with IC50 of 6 μM and 4 μM, respectively. [2] In a AsPC-1 mouse model, the combination therapy of 2-Methoxyestradiol and gemcitabine leads to a significant reduction of average tumor volume by 83% compared to the non-treated group, while 2-Methoxyestradiol (2 mg) alone leads to a growth inhibition of 63% with no evident toxicity. [6]
Protocol
Kinase Assay [1]
Microtubule depolymerizing activity
The effects of 2-Methoxyestradiol on cellular microtubule depolymerization are determined by indirect immunofluorescence techniques in rat aortic smooth muscle A-10 cells. Microtubules are visualized using a β-tubulin antibody. Three viewers determines the percent microtubule loss for each treatment concentration. The data are averaged and plotted as percent microtubule loss versus drug concentration and the EC50s for microtubule depolymerization calculated from the log dose–response curves.
Cell Assay [1]
Cell Lines
MDA-MB-435 and SK-OV-3
Concentrations
0-20 μM
Incubation Time
48 hours
Methods
The sulforhodamine B (SRB) assay is used to evaluate the antiproliferative activity of 2-Methoxyestradiol in the MDA-MB-435 and SK-OV-3 cell lines. Cells a plated into 96-well plates and allowed to grow and attach for 24 hours followed by addition of 2-Methoxyestradiol or vehicle controls. The cells are incubated with drugs for 48 hours and then the cellular protein is fixed, stained, and concentration determined by absorbance at 560 nm. Log dose–response curves are constructed for each experiment and the IC50 for inhibition of proliferation determined.
Animal Study [5]
Animal Models
9L-V6R cells are injected into the brains of Fischer 344 rats
Formulation
2-Methoxyestradiol is dissolved in DMSO.
Doses
≤600 mg/kg
Administration
Administered via i.p.
分子图谱
暂无数据
点击上传数据
参考文献
• Seeger H, et al. J Steroid Biochem Mol Biol. 2003, 84(2-3), 255-257.
• Mabjeesh NJ, et al. Cancer Cell. 2003, 3(4), 363-375.
• Salama SA, et al. Fertil Steril. 2012.
• Rao PN, et al. Steroids. 2002, 67(13-14), 1079-1089.
• Kang SH, et al. Cancer Res. 2006, 66(24),11991-11997.
• Fotopoulou C, et al. Anticancer Res. 2010, 30(11), 4619-4624.